These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 26099673)

  • 1. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
    Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
    Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
    [No Abstract]   [Full Text] [Related]  

  • 3. Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas.
    Rakheja R; Makis W; Tulbah R; Skamene S; Holcroft C; Nahal A; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2013 Jul; 201(1):170-7. PubMed ID: 23789672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
    Peterson JJ
    Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG PET/MR in initial staging of sarcoma: Initial experience and comparison with conventional imaging.
    Platzek I; Beuthien-Baumann B; Schramm G; Maus J; Laniado M; Kotzerke J; van den Hoff J; Schuler M
    Clin Imaging; 2017; 42():126-132. PubMed ID: 27951459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
    Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
    Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.
    Younis MH; Abu-Hijleh HA; Aldahamsheh OO; Abualruz A; Thalib L
    Med Princ Pract; 2020; 29(5):465-472. PubMed ID: 31887730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
    Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
    Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
    Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
    Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
    Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H
    AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET-CT in soft tissue sarcomas: staging, restaging, and prognostic value?
    Gabriel M; Rubello D
    Nucl Med Commun; 2016 Jan; 37(1):3-8. PubMed ID: 26457597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
    Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
    J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular imaging of sarcomas with FDG PET.
    Mendoza H; Nosov A; Pandit-Taskar N
    Skeletal Radiol; 2023 Mar; 52(3):461-475. PubMed ID: 36173459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis.
    Li YJ; Dai YL; Cheng YS; Zhang WB; Tu CQ
    Eur J Surg Oncol; 2016 Aug; 42(8):1103-14. PubMed ID: 27189833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Metser U; Kulanthaivelu R; Salawu A; Razak A; Mak V; Li X; Langer DL; MacCrostie P; Singnurkar A
    J Nucl Med; 2023 Sep; 64(9):1371-1377. PubMed ID: 37414444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of positron emission tomography in the management of patients with sarcoma.
    Benz MR; Tchekmedyian N; Eilber FC; Federman N; Czernin J; Tap WD
    Curr Opin Oncol; 2009 Jul; 21(4):345-51. PubMed ID: 19412096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
    Walter F; Czernin J; Hall T; Allen-Auerbach M; Walter MA; Dunkelmann S; Federman N
    J Pediatr Hematol Oncol; 2012 Mar; 34(2):131-6. PubMed ID: 22134608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis.
    Kubo T; Furuta T; Johan MP; Ochi M
    Eur J Cancer; 2016 May; 58():104-11. PubMed ID: 26990930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of
    Kassem TW; Abdelaziz O; Emad-Eldin S
    Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of
    Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
    Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.